

Keywords: primary care; diagnostic test; delay; referral; cancer

# Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data

G P Rubin<sup>\*1</sup>, C L Saunders<sup>2</sup>, G A Abel<sup>2</sup>, S McPhail<sup>3</sup>, G Lyratzopoulos<sup>2</sup> and R D Neal<sup>4</sup>

<sup>1</sup>Evaluation, Research and Development Unit, School of Medicine, Pharmacy and Health, Wolfson Research Institute, University of Durham, Queen's Campus, University Boulevard, Stockton-on-Tees TS17 6BH, UK; <sup>2</sup>Department of Public Health and Primary Care, Cambridge Centre for Health Services Research, University of Cambridge, Cambridge CB2 0SR, UK; <sup>3</sup>National Cancer Intelligence Network (NCIN), Public Health England, 5th Floor, Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK and <sup>4</sup>North Wales Centre for Primary Care Research, College of Health & Behavioural Sciences, Bangor University, Gwenvro Unit 5, Wrexham Technology Park, Wrexham LL13 7YP, UK

**Background:** For patients with symptoms of possible cancer who do not fulfil the criteria for urgent referral, initial investigation in primary care has been advocated in the United Kingdom and supported by additional resources. The consequence of this strategy for the timeliness of diagnosis is unknown.

**Methods:** We analysed data from the English National Audit of Cancer Diagnosis in Primary Care on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer relating to the ordering of investigations by the General Practitioner and their nature. Presenting symptoms were categorised according to National Institute for Health and Care Excellence (NICE) guidance on referral for suspected cancer. We used linear regression to estimate the mean difference in primary-care interval by cancer, after adjustment for age, gender, and the symptomatic presentation category.

**Results:** Primary-care investigations were undertaken in 3198/5036 (64%) of cases. The median primary-care interval was 16 days (IQR 5–45) for patients undergoing investigation and 0 days (IQR 0–10) for those not investigated. Among patients whose symptoms mandated urgent referral to secondary care according to NICE guidelines, between 37% (oesophagus) and 75% (pancreas) were first investigated in primary care. In multivariable linear regression analyses stratified by cancer site, adjustment for age, sex, and NICE referral category explained little of the observed prolongation associated with investigation.

**Interpretation:** For six specified cancers, investigation in primary care was associated with later referral for specialist assessment. This effect was independent of the nature of symptoms. Some patients for whom urgent referral is mandated by NICE guidance are nevertheless investigated before referral. Reducing the intervals between test order, test performance, and reporting can help reduce the prolongation of primary-care intervals associated with investigation use. Alternative models of assessment should be considered.

There are an estimated 300 million consultations in general practice in England annually (90% of all patient contacts with health care) (Hippisley-Cox and Vinogradova, 2009). A major

challenge for primary-care clinicians is to discriminate, often on the basis of undifferentiated or non-specific symptoms, between patients with self-limiting illness and those with significant disease.

\*Correspondence: Professor GP Rubin; E-mail: [g.p.rubin@durham.ac.uk](mailto:g.p.rubin@durham.ac.uk)

Received 29 July 2014; revised 7 November 2014; accepted 1 December 2014; published online 20 January 2015

© 2015 Cancer Research UK. All rights reserved 0007–0920/15



Cancer symptoms typically have low positive predictive values and present a particular challenge in this respect (Hamilton, 2009). Nevertheless, prompt identification and referral for investigation of patients with suspected cancer is a major public and policy concern (Department of Health, 2007; Macmillan Cancer Support, 2014), based on a widely held view that delays have a detrimental effect on outcome. The evidence is not as yet definitive. Although some studies have shown an association between longer time to diagnosis and poorer clinical outcomes (Richards *et al*, 1999; Torring *et al*, 2013), confounding by patients with advanced disease at presentation can make their interpretation problematic (Neal, 2009). Meanwhile, prolonged time to diagnosis results in psychological distress and sub-optimal patient experience (Risberg *et al*, 1996; Rarer Cancer Foundation, 2011). Clinical guidance for general practitioners (GPs) on high-risk features warranting urgent referral for suspected cancer has been produced in a number of countries, and in England by NICE in 2005 (National Institute for Health and Care Excellence (2005)). Many cancer patients, however, present to their GP with lower-risk features (Hamilton, 2010). A more recent approach to improving cancer outcomes in England has been to increase access for GPs to diagnostic tests supported by guidance on their use (Department of Health, 2012a).

In the 3 months before diagnosis, Danish patients with cancer have around 10 times as many diagnostic investigations as the reference population, some instigated by GPs (Christensen *et al*, 2012). Most studies of GPs' use of investigations has addressed issues of test use (Jellema *et al*, 2010) and efficiency (Verstappen *et al*, 2003; Schoen *et al*, 2004). It is uncertain, however, whether initial investigation of cancer symptoms in primary care delays referral for specialist assessment. This question is central to clinical practice and cancer diagnosis.

In order to answer the question of whether, in patients with symptoms suggestive of cancer, primary-care investigations are associated with less prompt referral, we analysed data from the English National Audit of Cancer Diagnosis in Primary Care, conducted during 2009/10 and containing information on 18 879 patients diagnosed with cancer in that period (Rubin *et al*, 2011).

## PATIENTS AND METHODS

The methods used in collection of the source data are described in detail elsewhere (Rubin *et al*, 2011). In brief, anonymous data were collected by GPs or other primary-care professionals in an estimated total of 1170 general practices (~14% of all practices in England) that participated voluntarily in an audit of cancer diagnosis in primary care. All patients of those practices, who were diagnosed with cancer, typically during a defined period of up to 12 months, were included in the audit. Patients with screen-detected cancer, *in situ* cancer, and non-melanoma skin cancer were excluded. The age, gender, and cancer diagnosis case-mix of the audited population is representative of the population-based cancer incidence statistics, and participating practices are similar to non-participating practices in their (former) cancer networks (Lyrtzopoulos *et al*, 2013a).

We analysed data on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer. These six cancer sites were selected because they each have a range of presenting symptoms from high to low risk, and because for each there is one or more investigation that may be appropriately ordered as part of the patient's assessment in primary care and that is generally available to GPs in England.

We analysed data on patients aged 15 years or older with completely observed information on primary-care interval values from 0 to 730 days (Lyrtzopoulos *et al*, 2013b). We defined primary-care interval as the period in days from first presentation

to a GP with a relevant symptom to the date of first specialist referral for further assessment. The audit also collected the date of the first appointment with a specialist, but did not collect the date of diagnosis.

Gender and age were recorded from the patient medical records, the latter categorised for this study into six groups 15–44, 45–54, 55–64, 65–74, 75–84 and 85+.

Data were extracted from the audit data set in relation to two questions 'Did the GP order any investigations' and 'If yes, please list the investigations in order'. Practice staff were asked to identify any investigations undertaken prior to referral. Responses to the first question were coded as yes, no, or missing, and responses to the second question were used to create five binary variables coding whether or not the patient had had any of five common investigations: blood test; chest X-ray; ultrasound scan; CT or MRI scan; endoscopic investigation.

**Clinical presentation.** Free text audit records in response to the question 'What was the main presenting symptom?' were categorised in two stages. First, and separately by cancer, the presenting symptom(s) was classified into between 20 and 37 groups (Appendix Table A1). These were agreed by three clinicians (GPR, RDN, GL) and then independently assigned by them. Disagreements were resolved by discussion between coders. Where more than one symptom was described, the main symptom was taken as the first stated, unless a NICE Clinical Guideline (CG)27-mandated ('alarm') symptom appeared later in the list.

Second, patients were classified on the basis of their presenting symptom(s) and age into five groups according to CG27; mandated referral; possibly mandated referral (insufficient information provided on qualifying conditions (e.g., severity, duration, frequency) to be definitive); mandated investigation; possibly mandated investigation (as above); no mandated action. Some presenting symptoms (e.g., ascites, haematemesis) were not specifically mentioned in CG27 as requiring urgent referral, but the clinical consensus was that this would be best practice. These were included in the 'mandated referral' group. Coding was age specific for those symptoms for which CG27 recommendations were age-conditional. For multivariable analysis, 'possible referrals' were grouped with 'no action' for ovarian and oesophageal cancers because of small numbers.

**Statistical analysis.** We describe the primary-care interval distribution using the mean, median, 25th, 75th, and 90th centiles. Stratified by cancer diagnosis, we calculated the percentages of patients investigated by their GP in each of the five NICE CG27 referral recommendation groups.

We calculated the mean difference in primary-care interval among those patients investigated in primary care and those who were not. To determine whether the association between primary-care investigations and primary-care interval can be attributed to different clinical presentations (i.e., whether patients who are most likely to be investigated are simply those who present with non-specific symptoms and have a longer primary-care interval for this reason), we used linear regression to estimate the mean difference in primary-care interval by investigation status, adjusting for age, gender, and the NICE referral category, separately by cancer.

95% Confidence intervals were estimated using bias corrected and accelerated bootstrap estimation, and where they exclude zero, the differences between the two groups were taken to be significant at  $P < 0.05$ . Analyses were repeated for 99.99% confidence intervals.

We performed a number of sensitivity analyses investigating the impact of how the primary-care interval, primary-care investigation use and clinical presentation were parameterised (see Appendix Tables for details). Further, we performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the

number of days between referral from primary care and first patient contact in secondary care). We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use.

## RESULTS

The derivation of the analysis sample is shown in Figure 1. In descriptive analyses, primary-care investigations were undertaken in 3198/5036 of included cases (64%), ranging from 43% for oesophageal cancer to 80% for lung cancer. The median primary-care interval across all six cancer sites was 16 (IQR 5–45) days for those who had one or more investigation, and 0 (IQR 0–10) days for those who had no investigation. The corresponding mean intervals were 41 days and 17 days, and did not differ by age or gender. The difference in the median interval by investigation status was considerably greater at the 75th (10 days non-investigated, 44 days investigated patients) and 90th centiles (45 days and 106 days, respectively) (Table 1).

In unadjusted analyses, individual investigations lengthened the mean primary-care interval by between 5 days (chest X-ray) and 32 days (endoscopy), whereas undertaking more than one test in primary care added a mean of 8 days (Table 2). For individual cancer sites, any investigation significantly extended the mean primary-care interval by between 20 days (ovarian) and 30 days (stomach) (Table 2). When individual cancers were considered by NICE referral category, investigation was more likely if NICE CG27 mandated this or if no action was mandated. The proportion of patients presenting with symptoms for which NICE CG27 mandates urgent referral was 10%, 9%, 5%, 64%, 24%, and 37% for colorectal, ovarian, lung, oesophageal, pancreatic, and stomach cancer, respectively. Nevertheless, a substantial proportion of patients whose symptoms mandated urgent referral were investigated in primary care, ranging from 37% (oesophagus) to 75% (pancreas) (Table 3).

In linear regression analyses, stratified by cancer, that adjusted for age, sex, and the NICE referral category, adjustment for these

factors explained very little of the mean observed additional days associated with investigation, but the effect for pancreatic cancer ceased to be significant (Table 4). Alternative parameterisations of the primary-care interval, investigation use, or clinical presentation categories made minimal difference to these findings (Appendix Tables A3–A5).

Among those patients for whom data on number of consultations prior to referral were available, 965/2095 (46.1%) of those consulting once were investigated, while 1058/1240 (85.3%) of those consulting 3+ times were investigated.

Finally, in order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals, we examined the association between investigations in primary care and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic). For all cancers, except pancreatic cancer, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated. We find no evidence that longer primary-care intervals are offset by shorter referral intervals in patients who are investigated in primary care (Appendix Table A6). Because date of diagnosis did not form part of the data items collected for the audit, we were unable to examine the effect of investigations on total diagnostic interval.

## DISCUSSION

We found that for six specified cancers, investigation in primary care of the presenting symptom(s) was associated with later referral for specialist assessment. This difference in the mean primary-care interval ranged from an additional 20 to 30 days depending on the cancer site, and was independent of whether the patient presented with alarm symptoms. For four of the six cancers studied, the difference increased with the number of tests undertaken.

The principle that patients with symptoms are initially assessed in primary care in order that only a proportion are then more extensively assessed by specialists (the gatekeeping function) is a key feature of health-care systems in which primary care features strongly. It contributes to their better health outcomes and efficiencies (Starfield *et al*, 2005), although an ecological association with poorer




Figure 1. Flow diagram: derivation of the analysis sample.

**Table 1. Patient characteristics, mean and median (percentile) primary-care interval**

	N	Primary-care interval				
		Mean	Median	25th Percentile	75th Percentile	90th Percentile
<b>All</b>	5036	32.5	8	0	34	87
<b>Sex</b>						
Female	2413	33.1	9	0	36	88
Male	2623	31.9	8	0	32	85
<b>Age</b>						
15–44	150	36.9	7.5	0	43	113
45–54	405	30.3	8	0	34	75
55–64	1030	31.1	8	0	33	85
65–74	1503	32.0	8	0	34	83
75–84	1430	33.6	9	0	36	88
85 +	518	34.2	7	0	32	100
<b>Cancer diagnosis</b>						
Colorectal	2111	33.0	6	0	30	94
Ovarian	345	21.5	7	0	25	54
Lung	1494	34.5	13	3	39	83
Oesophageal	513	26.3	6	0	31	75
Pancreatic	327	33.0	7	0	32	96
Stomach	246	43.2	13	0	58	132
<b>Investigations in primary care</b>						
No	1838	17.4	0	0	10	44
Yes	3198	41.2	16	5	45	106

cancer 1-year survival has also been described (Vedsted and Olesen, 2011). Investigation in primary care is most strongly associated with perceived medical need, although a minority of investigations are a consequence of patient preference (Little *et al*, 2004). Where the alternative is specialist referral, investigation in primary care may result in the primary-care interval being prolonged, since additional consultations are needed to communicate results, and multiple consultations are associated with longer primary-care intervals (Lyrtzopoulos *et al*, 2013b). We found that 85% of patients consulting three or more times had undergone investigation, compared with 46% of those consulting once. The literature is sparse on the effect of investigations in primary care on time to diagnosis, although a study of patients with colorectal cancer found that those who were not investigated by the faecal occult blood test had a significantly shorter median diagnostic interval than those who were (Hogberg *et al*, 2013). Further, a qualitative study of patients with testicular cancer identified waiting time for GP-requested ultrasonography as a factor in late diagnosis (Chapple *et al*, 2004). However, failure to investigate may be also associated with referral being deferred. In a study of GP-reported quality deviations in 5711 patients with cancer, failure to order relevant investigations was associated with a prolonged diagnostic interval (Jensen *et al*, 2014), whereas diagnostic delay for tuberculosis has been associated with failure of the first doctor consulted to order a sputum test or chest X-ray (Calder *et al*, 2000).

Strategies have been developed to expedite the investigation of patients with symptoms that could indicate cancer. In Denmark, ambulatory care facilities exist for the prompt investigation of patients with non-specific symptoms, alongside an urgent referral pathway for those with higher-risk symptoms (Danish National Board of Health, 2010). Walk-in access to chest X-ray for symptomatic members of the public aged >50 years has been provided through a local initiative in Leeds, UK, resulting in 8.6% of all community-ordered chest X-rays being taken this way (Cheyne *et al*, 2012). Dedicated centres that allow patients to access specialist assessment without physician referral have also been proposed by a panel of cancer experts in the United States, as a response to their Institute of Medicine report 'Crossing the Quality Chasm' (Bowles *et al*, 2008). The initiatives described address a

range of constraints to prompt diagnosis, and they operate within complex health systems. Their impact can only be fully understood in the context of the overall diagnostic pathway, something we were unable to do in this study.

**Strengths and limitations.** This is the first study to explicitly determine the effect of GP-initiated investigations on speed of referral for specialist assessment. Its strengths include the relatively large number of cases for each cancer site, the completeness of data on presenting symptom(s) and consultations, and the direct extraction of information from the primary-care record. The study team included experienced clinicians, ensuring that the complex task of coding clinical data was accurately completed.

There are several limitations that we acknowledge. Because participation of general practices in the audit was voluntary and potentially biased towards those most interested in cancer care, the findings may represent 'better' practice. However, the audit patient population was similar to the incident cancer cases in England (Rubin *et al*, 2011) while the characteristics of participating practices were similar to non-participating practices of the same (former) cancer network (Lyrtzopoulos *et al*, 2013b). Nevertheless, these practices may have been more interested in cancer diagnosis and management and more likely to investigate patients with suspicious symptoms. Practices were typically required to audit a continuous sample of cases occurring in a specified period, and there was no evidence of significant exclusion of cases (Rubin *et al*, 2011).

Data were extracted from clinical records and hospital correspondence. There was no validation of the data, but in all cases data were reviewed at a practice meeting and checked for completeness and face validity by a cancer network clinical lead. There is scope for errors of interpretation during data extraction, for example, in deciding on the date of first consultation. The potential sources of error in studies of diagnostic intervals have been well described (Weller *et al*, 2012), but the methodology used by the audit conformed to best practice in the field (Weller *et al*, 2012). Finally, 1100 (17.9%) cases were excluded because both of the dates required to estimate the primary-care interval were not available. Many of these were patients whose pathway to diagnosis

**Table 2. Primary-care investigations and primary-care interval, by cancer**

	All			Colorectal			Ovarian			Lung			Oesophageal			Pancreatic			Stomach		
	N	Mean	Median	N	Mean	Median	N	Mean	Median	N	Mean	Median	N	Mean	Median	N	Mean	Median	N	Mean	Median
Any investigation in primary care	1838	17.4	0	967	18.6	0	105	7.5	0	294	17.1	1	293	15.5	0	81	15.5	0	98	24.9	0
	3198	41.2	16	1144	45.3	17	240	27.7	13	1200	38.9	16	220	40.7	21	246	38.8	13	148	55.3	22
Blood test	2996	26.3	4	1140	23.4	1	195	19.5	2	1058	32.6	11	350	19.4	1	122	23	0	131	32.7	2
	2040	41.6	15	971	44.4	16	150	24.1	13	436	39.5	17	163	41.2	21	205	39	12	115	55.2	21
Chest X-ray	3908	31.4	6	2070	33	6	327	21.1	7	464	31.9	7	494	25.9	4	314	31.5	7	239	42.8	12
	1128	36.2	16	41	36.3	12	18	29.2	15.5	1030	35.8	15	19	37	27	13	68.9	39	7	56.6	19
Ultrasound	4546	30.9	7	1979	31.8	5	186	14.4	2	1455	34.3	13	497	25.3	5	211	20.8	3	218	35.7	9
	490	47.7	20	132	50.8	21.5	159	29.9	14	39	44.3	22	16	56.8	33	116	55.3	21	28	101.5	57
CT/MRI	4928	31.9	8	2094	32.5	6	338	20.9	7	1420	33.6	12	511	26.3	6	320	33.2	7	245	43.4	13
	108	56.9	35	17	95.1	39	7	54.1	34	74	52.9	35	2	20.5	20.5	7	26	13	1	5	5
Endoscopy	4861	31.4	8	2022	31.1	5	341	21.7	7	1484	34.4	13	478	25.1	5	314	30.8	7	222	43.5	12
	175	63.1	20	89	76.7	20	4	7.5	7.5	10	56.4	40.5	35	43.2	15	13	86.7	49	24	40.5	19.5
Count of any of the above five investigations	1952	19.5	0	1031	20	0	108	8.3	0	312	22.4	2	315	17.7	0	82	15.9	0	104	25.9	0.5
	2301	38.7	14	923	42.4	14	147	30.1	11	809	37.7	14	162	37.3	15	148	22.9	7.5	112	49.4	23
	783	46.9	21	157	63.9	23	90	23.3	14	373	38.1	20	36	52.1	32.5	97	63	22	30	79.8	21

Abbreviations: CT = computed tomography; MRI = magnetic resonance tomography.  
 aThe numbers in these two groups are slightly different as the first two rows include patients who have had any investigation in primary care, but the bottom three rows are counts based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).

**Table 3. Use of primary-care investigations and the NICE guideline referral category based on clinical presentation, by cancer**

	Action specified by NICE guidelines under NICE CG27 based on patient characteristics and clinical presentation	GP investigations performed		
		All N	N	%
Colorectal	Mandated referral under NICE guidelines (or good clinical practice)	208	99	47.6
	Possible referral under NICE guidelines	1105	581	52.6
	Mandated investigation under NICE guidelines	200	90	45.0
	Possible investigation under NICE guidelines	0		
	No action under NICE guidelines	598	374	62.5
Ovarian	Mandated referral under NICE guidelines (or good clinical practice)	31	12	38.7
	Possible referral under NICE guidelines	5	0	
	Mandated investigation under NICE guidelines	26	16	61.5
	Possible investigation under NICE guidelines	0		
	No action under NICE guidelines	283	212	74.9
Lung	Mandated referral under NICE guidelines (or good clinical practice)	76	39	51.3
	Possible referral under NICE guidelines	0		
	Mandated investigation under NICE guidelines	223	195	87.4
	Possible investigation under NICE guidelines	916	779	85.0
	No action under NICE guidelines	279	187	67.0
Oesophageal	Mandated referral under NICE guidelines (or good clinical practice)	328	121	36.9
	Possible referral under NICE guidelines	9	0	0.0
	Mandated investigation under NICE guidelines	0		
	Possible investigation under NICE guidelines	69	36	52.2
	No action under NICE guidelines	107	63	58.9
Pancreatic	Mandated referral under NICE guidelines (or good clinical practice)	79	59	74.7
	Possible referral under NICE guidelines	100	65	65.0
	Mandated investigation under NICE guidelines	0		
	Possible investigation under NICE guidelines	0		
	No action under NICE guidelines	148	122	82.4
Stomach	Mandated referral under NICE guidelines (or good clinical practice)	92	45	48.9
	Possible referral under NICE guidelines	21	15	71.4
	Mandated investigation under NICE guidelines	0		
	Possible investigation under NICE guidelines	40	26	65.0
	No action under NICE guidelines	93	62	66.7

Abbreviations: GP = general practitioner; NICE = National Institute for Health and Care Excellence.

bypassed primary care, for example, through direct presentation to an emergency department. Others may have been seen by the GP, but the omission of dates of the first encounter and/or referral was not identified during the checking process prior to submission of data to the audit.

All investigations included were part of the primary-care appraisal process, but no judgement was made on their appropriateness or their context within the episode of care. It is possible that some were unhelpful or irrelevant to the diagnostic process and unnecessarily prolonged the primary-care interval. Details of the precise nature of blood or urine tests or the sites examined by CT, MRI, or endoscopy were not a specific requirement of practices participating in the audit.

Because the audit data were provided in an anonymous form, we were unable to link them to cancer registration and hospital record-derived data. This would have allowed us to determine, for those patients not investigated in primary care, whether investigation(s) were then undertaken in secondary or tertiary care and the effect of investigations in different settings on the total diagnostic interval. However, we observed that use of investigations, although adding to the length of the primary-care interval, did not result in a shorter referral interval. Moreover, for the hypothesis to be true that patients investigated in primary-care experience shorter secondary-care delays, and therefore no overall lengthening of the total diagnostic interval, either or both of the referral interval and the within-hospital interval to diagnosis would need to be substantially shorter for those patients with primary-care investigations compared with those without. These conditions are unlikely. First, we have observed a net lengthening of referral interval resulting from investigations for five out of six cancers.

Second, as use of investigations is associated with extending of the primary-care interval by a median of +16 days and a mean of +24 days, within-hospital diagnostic processes would need to be extraordinarily fast to compensate for these prolonged intervals. It should also be noted that in 2011/12 87.3% of patients commenced treatment within 62 days of referral, and 98.4% commenced treatment within 31 days of a diagnosis being made (Department of Health, 2012b). Moreover, the most frequent primary-care investigations were blood tests and chest X-rays, tests that do not typically provide the definitive diagnostic information necessary to establish the diagnosis of cancer, and would be unlikely to result in any substantial shortening of diagnostic intervals within secondary or tertiary care.

We selected the NICE referral category as our primary method for categorising patients' presenting symptoms. We adjusted for symptom status using a range of complementary analytical approaches, all of which indicated that the degree of confounding by symptom status (in respect of the association between investigation and prolonged primary-care interval) is trivial. In other words, whether patients present with non-specific symptoms or obvious alarm symptoms, investigations are always associated with a longer primary-care interval.

**Implications for practice.** Our findings are generalisable to health systems in which GPs act as gatekeepers to specialist care, but may be modified by differences in access to diagnostic tests. A substantial proportion of patients underwent investigation when their symptoms fulfilled NICE CG27 criteria for urgent referral. There are several possible explanations for this. Disparaging views from specialists about 'abuse' by GPs of the urgent referral pathway

**Table 4. Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age, sex and NICE guideline referral category**

		Mean additional primary-care interval (in days) among patients where investigations were performed			
		Number of cases	Unadjusted	Adjusted for age, sex, and clinical presentation	P-value <sup>a</sup>
Colorectal	Not investigated	967	Reference	Reference	P<0.0001
	Investigated	1144	26.7 (20.8–33.0)	25.7 (19.5–31.7)	
Ovarian <sup>b</sup>	Not investigated	105	Reference	Reference	P<0.0001
	Investigated	240	20.1 (13.6–27.5)	18.4 (12.2–25.5)	
Lung	Not investigated	294	Reference	Reference	P<0.0001
	Investigated	1200	21.8 (15.3–27.6)	23.6 (16.8–30.0)	
Oesophageal <sup>b</sup>	Not investigated	293	Reference	Reference	P<0.0001
	Investigated	220	25.3 (16.7–34.8)	22.3 (13.2–32.4)	
Pancreatic <sup>c</sup>	Not investigated	81	Reference	Reference	P>0.05
	Investigated	246	23.2 (5.0–38.1)	17.1 (–1.9–30.6)	
Stomach	Not investigated	98	Reference	Reference	P<0.0001
	Investigated	148	30.4 (15.1–48.2)	29.3 (14.0–45.8)	

Abbreviation: NICE = National Institute for Health and Care Excellence.

<sup>a</sup>95% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The P-value (P>0.05) presented for pancreatic cancer reflects that this 95% confidence interval crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99% confidence intervals were re-estimated for the same model and these also did not cross zero, P<0.0001 is correspondingly presented.

<sup>b</sup>Possible referrals' grouped with 'No action' in multivariable analysis because of small numbers.

<sup>c</sup>Age 15–44 years grouped with age 55–64 years because of small numbers.

may make some prefer to have additional evidence in the form of a confirmatory test result before making a referral (Mathew and Desai, 2009). The NICE criteria typically represent a risk of cancer in the region of 5–10%, the large majority not having the disease, and some GPs may use investigations as means of increasing the probability of cancer prior to making a decision about referral. It is also possible that some patients present in a context that causes the GP to modify their preferred course of action. For example, the patient may have been investigated in the past for the same problem, have severe co-morbidities, or may be reluctant to be referred to a specialist. Some GPs may consider it desirable, or have been advised that it is, for the results of baseline investigations to be available at the first specialist attendance (Barking, Havering and Redbridge University Hospital, 2014). Significant event analyses and case-note review studies are required to further establish the circumstances surrounding such 'guideline violations' (Mitchell *et al*, 2013; Singh *et al*, 2013).

Finally, certain investigations available to GPs are the definitive diagnostic tests, e.g., gastroscopy for suspected oesophagogastric cancer, and may be as readily available in primary as in specialist care. Other diagnostic tests, however, take longer to complete when ordered from primary care and may not be sufficiently comprehensive. In England, the median time from request to test for non-obstetric ultrasound investigation is longer for GP requests (19–27 days) than for all request sources combined (12–16 days) (NHS England, 2013). If investigations are undertaken in patients for whom urgent referral is indicated, the request should be concurrent with referral.

Because tests ordered in primary care may not be done or reported as promptly as those ordered from secondary care, our findings point to a need for investigative services to be provided to a comparable standard regardless of source of request. This should be accompanied by improved systems in primary care that ensure that a patient is rapidly reviewed once results are received. They also provide some support for models of service delivery in England that permit the rapid specialist assessment of patients with lower-risk symptoms, either by a lowering of the thresholds for urgent (2 weeks) referral for suspected cancer or the provision of diagnostic centres.

Time may be used as a diagnostic tool in primary care (Heneghan *et al*, 2009). Symptoms are seen by GPs at an earlier stage of development than in secondary care, and time allows the clinician to observe whether relatively undifferentiated symptoms develop more specific characteristics or resolve spontaneously. Investigations may form a part of this temporising approach while also being part of a safety-netting strategy (Almond *et al*, 2009).

These findings are the first step in determining the most effective diagnostic strategies for managing patients with symptomatic presentation of cancer. It will be important to understand the impact of primary-care investigation on secondary-care intervals, since these may plausibly be shortened, and on total diagnostic delay. Until then, no firm recommendations can be made on the merits or demerits of primary-care investigation. There is a need to understand the comparative clinical and health economic efficiency of strategies that encourage early primary-care investigation, compared with those that encourage either expectant management with limited testing and urgent referral if symptoms persist or worsen, or early referral without prior investigation.

## ACKNOWLEDGEMENTS

RDN receives funding from Public Health Wales and Betsi Cadwaladr University Health Board. GL is supported by a Post-Doctoral Fellowship by the National Institute for Health Research (PDF-2011-04-047). We are grateful to all primary-care professionals in participating practices for collecting, collating and submitting anonymous data to the National Audit of Cancer Diagnosis in Primary Care; Cancer Networks, the Royal College of General Practitioners and the National Cancer Action Team for supporting the audit, and the National Clinical Intelligence Network (NCIN) for providing the data. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the RCGP, the National Institute for Health Research or the Department of Health.

## CONFLICT OF INTEREST

From March 2012 to March 2014 GPR was the Royal College of General Practitioners Clinical Lead for Cancer and was a national advocate for the role of the GP in cancer diagnosis. The remaining authors declare no conflict of interest.

## AUTHOR CONTRIBUTIONS

GPR, GL, RDN, GAA and CS designed the study. GL, GAA and CLS analysed the data and all authors interpreted it. GPR wrote the first draft with additions and revisions by all authors.

## REFERENCES

- Almond S, Mant D, Thompson M (2009) Diagnostic safety-netting. *Br J Gen Pract* **59**: 872–874.
- Barking, Havering and Redbridge University Hospital (2014) Guidelines for referral of suspected upper GI cancer <http://www.bhrhospitals.nhs.uk/Downloads/services/bhrut-cancer-form-uppergi-0409.pdf>.
- Bowles EJA, Tuzzio L, Wiese CJ, Kirilin B, Greene SM, Clauser SB, Wagner EH (2008) Understanding high quality cancer care. *Cancer* **112**: 934–942.
- Calder L, Gao W, Simmons G (2000) Tuberculosis: reasons for diagnostic delay in Auckland. *NZ Med J* **113**: 83–85.
- Chapple A, Ziebland S, McPherson A (2004) Qualitative study of men's perceptions of why treatment delays occur in the UK for testicular cancer. *Br J Gen Pract* **54**: 25–32.
- Cheyne L, Foster C, Lovatt V, Hewitt F, Cresswell L, Fullard B, Fear J, Darby M, Robertson R, Plant PK, Milton R, Callister MEJ (2012) Improved lung cancer survival and reduced emergency diagnoses resulting from an early diagnosis campaign in Leeds 2011. *Thorax* **67**(Suppl 2): A44.
- Christensen KG, Fenger-Gron M, Flarup KR, Vedsted P (2012) Use of general practice, diagnostic investigations and hospital services before and after cancer diagnosis—a population-based nationwide registry study of 127000 incident adult cancer patients. *BMC Health Serv Res* **12**: 224.
- Danish National Board of Health (2010) *Kræftplan III. Styrket indsats på kræftområdet – et sundhedsfagligt oplæg*. The Danish National Board of Health: Copenhagen, Denmark.
- Department of Health (2007) *Cancer Reform Strategy*. Department of Health: London, UK.
- Department of Health (2012a) *Direct Access to Diagnostic Tests for Cancer: Best Practice Referral Pathways for General Practitioners (Gateway Ref 16913)*. Department of Health: London, UK.
- Department of Health (2012b) *Waiting Times for Cancer Services 2011–2012*. Department of Health: London, UK.
- Hamilton W (2009) The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. *Br J Cancer* **101**: S80–S86.
- Hamilton W (2010) Cancer diagnosis in primary care. *Br J Gen Pract* **60**: 121–128.
- Heneghan C, Glasziou P, Thompson M, Rose P, Balla J, Lasserson D, Scott C, Perera R (2009) Diagnostic strategies used in primary care. *BMJ* **338**: b946.
- Hippisley-Cox J, Vinogradova Y (2009) *Trends in Consultation Rates in General Practice 1995 to 2008: Analysis of the QResearch<sup>®</sup> database*. NHS Information Centre: London.
- Hogberg C, Karling P, Rutefgard J, Lilja M, Ljung T (2013) Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer. *Scand J Primary Health Care* **31**: 209–214.
- Jellema P, van der Windt D, Bruinvels DJ, Mallen CD, van Weyenberg SJ, de Vet HC (2010) Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. *BMJ* **340**: 795.
- Jensen H, Nissen A, Vedsted P (2014) Quality deviations in cancer diagnosis. *Br J Gen Pract* **64**: e92–e98.
- Little P, Dorward M, Warner G, Stephens K, Senior J, Moore M (2004) Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study. *BMJ* **328**: 444.
- Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP (2013a) Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. *BMJ Open* **3**: e002861.
- Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP (2013b) Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. *Br J Cancer* **108**: 686–690.
- Macmillan Cancer Support (2014) *Cancer in the UK*. Macmillan Cancer Support: London, UK. <http://www.macmillan.org.uk/Documents/AboutUs/WhatWeDo/CancerintheUK2014.pdf>
- Mathew A, Desai KM. An audit of urology two week wait referrals in a large teaching hospital in England. *Ann R Coll Surg Engl* (2009) **91**: 310–312.
- Mitchell ED, Rubin G, Macleod U. Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports. *Br J Gen Pract* (2013) **63**(606): e37–e46.
- National Institute for Health and Care Excellence (2005) *Clinical Guideline 27: Referral Guidelines for Suspected Cancer*. NICE: London, UK.
- Neal RD. Do diagnostic delays in cancer matter? *Br J Cancer* (2009) **101**(Suppl 2): S9–S12.
- NHS England (2013) *Diagnostic Imaging Dataset Statistical Release 2013*. NHS England: London, UK.
- Rarer Cancer Foundation (2011) *Primary cause? An Audit of the Experience in Primary Care of Rarer Cancer Patients*. <http://www.rarercancers.org.uk/images/stories/cdf/p8and9/primary%20cause%20-%20final.pdf>.
- Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet* (1999) **353**(9159): 1119–1126.
- Risberg T, Sørbye SW, Norum J, Wist EA. Diagnostic delay causes more psychological distress in female than in male cancer patients. *Anticancer Res* (1996) **16**(2): 995–999.
- Rubin GP, Elliott K, McPhail S (2011) *National Audit of Cancer Diagnosis in Primary Care*. Royal College of General Practitioners: London, UK.
- Schoen C, Osborn R, Huynh PT, Doty M, Davis K, Zapert K, Peugh J (2004) Primary care and health system performance: adults' experiences in five countries. *Health Affairs* **W4**: 487–503.
- Singh H, Giardina TD, Meyer AN, Forjuoh SN, Reis MD, Thomas EJ. Types and origins of diagnostic errors in primary care settings. *JAMA Intern Med* (2013) **173**(6): 418–425.
- Starfield B, Shi L, Macinko J (2005) Contribution of primary care to health systems and health. *Milbank Quarterly* **83**: 457–502.
- Torrington ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P (2013) Evidence for increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. *Eur J Cancer* **49**: 2187–2198.
- Vedsted P, Olesen F (2011) Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. *Br J Gen Pract* **61**: e508–e512.
- Verstappen WH, van der Wijden T, Sijbrandij J, Smeele I, Hermsen J, Grimshaw J, Grol RP (2003) Effect of a practice-based strategy on test ordering performance of primary care physicians: a randomised trial. *JAMA* **289**: 2407–2412.
- Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, Hiom S, Muth C, Beyer M, Neal RD (2012) The Aarhus Statement: improving design and reporting of studies on early cancer diagnosis. *Br J Cancer* **106**: 1262–1267.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>



## APPENDIX

Table A1. Symptom groups by cancer

Oesophageal and gastric cancer	Lung cancer	Ovarian cancer	Colorectal cancer	Pancreatic cancer
Dysphagia	Haemoptysis	Ultrasound suggestive of ovarian cancer	Rectal bleeding	Obstructive jaundice
Early satiety	Chest/shoulder pain	Post-menopausal bleeding	Altered bowel habit (to looser stool)	Thromboembolic disease
Nausea, vomiting	Dyspnoea	Persistent intermenstrual bleeding (with a negative pelvic examination)	Abdominal mass	Bleeding per rectum/melaena
Dyspepsia	Weight loss	Abdominal or pelvic mass not of gastroenterological or urological origin	Rectal mass	Diabetic ketoacidosis/new onset diabetes/loss of known diabetes control
Reflux	Chest signs	Abdominal or pelvic pain or discomfort	Anaemia	Altered bowel habit
Pain (epigastric, abdominal, chest)	Hoarseness	Abdominal bloating/distension/swelling/fullness	Weight loss	Nausea and vomiting
Anorexia	Clubbing	Urinary symptoms (including incontinence and retention)	Abdominal pain or tenderness	Gastro-oesophageal reflux disease
Fatigue, malaise	Chest X-ray/supra-clavicular lymph nodes	Unexplained weight loss	Bloating/distension	General malaise
Weight loss	Cough	Fatigue/tiredness/malaise/unwell/exhaustion	Malaise	Bloating
Bowel disturbance	Features suggesting metastases	Change in bowel habit to diarrhoea or alternating diarrhoea/constipation	Asymptomatic or incidental, including surveillance	Biliary colic
Iron deficiency anaemia	Abnormal chest X-ray		Acute surgical/medical emergency	Cough/shortness of breath
Haematemesis/melaena	Superior vena cava obstruction	Vaginal discharge or other abnormal vaginal bleeding	Constipation	Weight loss
Dizziness	Stridor	Anaemia	Nausea/vomiting	Urinary tract infection/other urinary symptoms
Upper abdominal mass	Loss of appetite	Chest symptoms	Other pain	anaemia
Asymptomatic or incidental finding	Thrombocytosis	Pulmonary embolus or deep vein thrombosis	Defaecation problems	Back pain
Pain (other)	Abnormal spirometry	Infertility	Anorexia	Abdominal pain
Barrett's	Asymptomatic or incidental	Nausea and/or vomiting	Mucus	Abdominal mass
Respiratory symptoms	Hyponatraemia	Asymptomatic or incidental	Collapse	Asymptomatic or incidental
Bloating	Respiratory infection	Ascites	Respiratory symptoms	Anorexia
Belching	Exacerbation of chronic obstructive pulmonary disease	Anorexia	Haemorrhoids	Dysphagia
Throat symptoms	Abdominal pain	Other/missing/not stated/not known	Urinary symptoms	Change in bowel habit
Hiatus hernia	Back pain		Liver	Dyspepsia
Odynophagia	Liver symptoms/signs		Upper gastrointestinal symptoms	
Other/missing/not stated/not known	Confusion		Disordered sensation lower limbs	Liver
	Malaise		Ascites	Pancreatitis/chronic
	Collapse		Colitis/inflammatory bowel disease	Steatorrhoea
	Change in bowel habit		Other/missing/not stated/not known	Lymphadenopathy
	Pain (other)			Other/missing/not stated/not known
	Urinary symptoms			
	Headache			
	Lower limb oedema			

	Sweats/fever			
	Anaemia			
	Upper gastrointestinal symptoms			
	Lump			
	Nausea or vomiting			
	Cardiac abnormalities			
	Neurological			
	ENT symptoms			
	Other/missing/not stated/not known			
Abbreviation: ENT = ear, nose and throat.				

**Table A2. NICE guideline referral categories based on clinical presentation**

Mandated referral under NICE guidelines (or good clinical practice)	Clear evidence for mandated urgent referral as per NICE CG27
Possible referral under NICE guidelines	Good clinical medicine would mandate urgent referral Possible mandated urgent referral as per NICE CG27—but duration dependent Possible mandated urgent referral as per NICE CG27—but severity dependent Possible mandated urgent referral as per NICE CG27—but location dependent Possible mandated urgent referral as per NICE CG27—but dependent upon sense of abnormality Possible mandated urgent referral as per NICE CG27—other
Mandated investigation under NICE guidelines	Clear evidence of mandated investigation as per NICE CG27
Possible investigation under NICE guidelines	Possible mandated investigation as per NICE CG27—but duration dependent Possible mandated investigation as per NICE CG27—but severity dependent Possible mandated investigation as per NICE CG27—but location dependent Possible mandated investigation as per NICE CG27—but dependent upon sense of abnormality Possible mandated investigation as per NICE CG27—other
No action under NICE guidelines	No mandated action from NICE CG27
Abbreviation: NICE = National Institute for Health and Care Excellence.	

**Sensitivity analysis**

We performed several sensitivity analyses for key analytical aspects, using alternative parameterisations of the three variables:

- Primary-care interval
- Investigation use in primary care
- Clinical presentation

Primary-care interval is positively skewed, with a large number of zero values. The analysis (presented in the main text) examines ‘mean differences’ in primary-care interval associated with investigation use. Although the use of bootstrap estimation means that inference is appropriate, we also performed a sensitivity analysis based on a binary categorisation of primary-care interval into 0–14 and 15+ days. Results are presented in Appendix Table A3.

Investigation use can be parameterised as a binary yes/no variable (as in the main text)—or as an ordered categorical variable based on the number of investigations (used in sensitivity analysis). Specifically, the number of investigations was parameterised as an ordered categorical variable (0, 1, 2 or more investigations) based on counts of the five individual investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy). Results are presented in Appendix Table A4.

In the main analysis presented, we adjust for clinical presentation using five groups based on NICE guideline referral categories

(Appendix Table A2). In sensitivity analysis adjustment for clinical presentation was made on the basis of presenting symptom(s) (Appendix Table A1) and based on this classification, but allowing the effect of symptom to vary by age. We also explored adjusting for the more detailed 14-group classification based on NICE guidelines (Appendix Table A2). Results are presented in Appendix Table A6.

**Supplementary analysis**

We performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the number of days between referral from primary care and the first patient contact in secondary care). If this hypothesis were true, it might offset the differences in primary-care interval. We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use. Results are presented in Appendix Table A6.

For ovarian and oesophageal cancers ‘possible referrals’ were grouped with ‘no action’ in multivariable analysis because of small numbers, similarly age 15–44 years is grouped with age 55–64 years for pancreatic cancer because of small numbers.

**Table A3. Sensitivity analysis using alternative parameterisation of primary-care interval**

		Number of cases	Adjusted for age, sex, and the NICE referral category based on presenting symptoms	OR (95% CI) for 15+ days primary-care interval (compared with 0-14 days) adjusted for age, sex, and clinical presentation	P-value
Colorectal	Not investigated Investigated	967 1144	<i>Reference</i> <i>25.7 (19.5-31.7)</i>	Reference 4.6 (3.7-5.6)	<0.001
Ovarian	Not investigated Investigated	105 240	<i>Reference</i> <i>18.4 (12.2-25.5)</i>	Reference 4.2 (2.3-7.9)	<0.001
Lung	Not investigated Investigated	294 1200	<i>Reference</i> <i>23.6 (16.8-30.0)</i>	Reference 3.8 (2.8-5.2)	<0.001
Oesophageal	Not investigated Investigated	293 220	<i>Reference</i> <i>22.3 (13.2-32.4)</i>	Reference 4.1 (2.8-6.1)	<0.001
Pancreatic	Not investigated Investigated	81 246	<i>Reference</i> <i>17.1 (-1.9-30.6)</i>	Reference 4.4 (2.1-9.2)	<0.001
Stomach	Not investigated Investigated	98 148	<i>Reference</i> <i>29.3 (14.0-45.8)</i>	Reference 5.7 (3.1-10.6)	<0.001

Abbreviations: CI = confidence interval; NICE = National Institute for Health and Care Excellence; OR = odds ratio. Results presented in bold italics are those from Table 4 This sensitivity analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.

**Table A4. Sensitivity analysis using alternative parameterisation of investigation use in primary care**

		Number of cases	Adjusted for age, sex, and the NICE referral category based on presenting symptoms		Number of cases	Adjusted for age, sex, and the NICE referral category based on presenting symptoms
Colorectal	Not investigated <sup>a</sup> Investigated	967 1144	<i>Reference</i> <i>25.7 (19.5-31.7)</i>	No investigations <sup>a</sup> One Two +	1031 923 157	Reference 21.3 (15.1-30.0) 43.5 (28.3-58.2)
Ovarian	Not investigated Investigated	105 240	<i>Reference</i> <i>18.4 (12.2-25.5)</i>	No investigations One Two +	108 147 90	Reference 20.1 (11.0-30.6) 13.6 (6.0-21.2)
Lung	Not investigated Investigated	294 1200	<i>Reference</i> <i>23.6 (16.8-30.0)</i>	No investigations One Two +	312 809 373	Reference 17.0 (6.9-24.7) 16.2 (6.6-24.8)
Oesophageal	Not investigated Investigated	293 220	<i>Reference</i> <i>22.3 (13.2-32.4)</i>	No investigations One Two +	315 162 36	Reference 17.1 (7.7-28.8) 29.9 (10.3-58.1)
Pancreatic	Not investigated Investigated	81 246	<i>Reference</i> <i>17.1 (-1.9-30.6)</i>	No investigations One Two +	82 148 97	Reference 4.8 (-14.4-16.7) 41.3 (20.2-62.5)
Stomach	Not investigated Investigated	98 148	<i>Reference</i> <i>29.3 (14.0-45.8)</i>	No investigations One Two +	104 112 30	Reference 21.2 (6.2-35.8) 56.0 (16.7-107.8)

Abbreviations: CT = computed tomography; MRI = magnetic resonance tomography; NICE = National Institute for Health and Care Excellence. <sup>a</sup>The numbers in these two groups (for all cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy). Results presented in bold italics are those from Table 4 With a single exception (pancreatic cancer) primary-care investigations were associated with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care investigations, compared with those who had one. For lung and ovarian cancer, investigation use was associated with longer primary-care interval, but delay was not additionally longer among people with two or more primary-care investigations, compared with only one.

**Table A5. Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category**

		Number of cases	Adjusted for age, sex, and main (5) NICE referral categories based on presenting symptoms	Adjusting for age and sex and detailed (14) NICE referral categories	Adjusting age and sex and for clinical presentation using main presenting symptom	Adjusting for age and sex and for clinical presentation using main presenting symptom (allowing the effect of symptom to vary by age)
Colorectal	Not investigated	967	<i>Reference</i>	Reference 24.6	Reference 26.5	Reference 26.2
	Investigated	1144	<b>25.7 (19.5–31.7)</b>			
Ovarian	Not investigated	105	<i>Reference</i>	Reference 18.5	Reference 17.8	Reference 18.1
	Investigated	240	<b>18.4 (12.2–25.5)</b>			
Lung	Not investigated	294	<i>Reference</i>	Reference 23.9	Reference 20.1	Reference 20.8
	Investigated	1200	<b>23.6 (16.8–30.0)</b>			
Oesophageal	Not investigated	293	<i>Reference</i>	Reference 22.7	Reference 23.4	Reference 23.0
	Investigated	220	<b>22.3 (13.2–32.4)</b>			
Pancreatic	Not investigated	81	<i>Reference</i>	Reference 14.9	Reference 13.9	Reference 16.0
	Investigated	246	<b>17.1 (–1.9–30.6)</b>			
Stomach	Not investigated	98	<i>Reference</i>	Reference 28.4	Reference 27.7	Reference 28.0
	Investigated	148	<b>29.3 (14.0–45.8)</b>			

Abbreviation: NICE = National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4. Different approaches to adjusting for clinical presentation in different ways have minimal impact on the association between primary-care investigation use and primary-care interval.

**Table A6. Supplementary analysis. The association between investigation use and referral interval (defined as period from day of referral to day when patient was first seen at hospital)**

		Primary-care interval		Referral interval		Pre-hospital interval	
		Number of cases	Adjusted for age, sex, and the NICE referral category of presenting symptoms	Number of cases	Adjusted for age, sex, and the NICE referral category of presenting symptoms	Number of cases	Adjusted for age, sex, and the NICE referral category of presenting symptoms
Colorectal	Not investigated	967	<i>Reference</i>	946	Reference	946	Reference
	Investigated	1144	<b>25.7 (19.5–31.7)</b>	1120	5.1 (2.1–8.7)	1120	28.4 (21.9–34.9)
Ovarian	Not investigated	105	<i>Reference</i>	101	Reference	101	Reference
	Investigated	240	<b>18.4 (12.2–25.5)</b>	236	1.6 (–5.0–4.6)	238	18.7 (10.0–27.4)
Lung	Not investigated	294	<i>Reference</i>	290	Reference	290	Reference
	Investigated	1200	<b>23.6 (16.8–30.0)</b>	1165	4.5 (–1.6–10.1)	1165	28.6 (19.4–36.8)
Oesophageal	Not investigated	293	<i>Reference</i>	283	Reference	283	Reference
	Investigated	220	<b>22.3 (13.2–32.4)</b>	215	4.5 (–2.2–13.3)	215	29.1 (18.2–42.5)
Pancreatic	Not investigated	81	<i>Reference</i>	78	Reference	78	Reference
	Investigated	246	<b>17.1 (–1.9–30.6)</b>	241	–9.4 (–33.2–3.1)	241	7.4 (–15.6–30.3)
Stomach	Not investigated	98	<i>Reference</i>	95	Reference	95	Reference
	Investigated	148	<b>29.3 (14.0–45.8)</b>	141	11.9 (5.1–26.7)	141	41.8 (21.5–63.4)

Abbreviation: NICE = National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4.

In order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals among investigated patients, we examined the association between investigations in primary care and the referral interval, and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic).

Although the differences in referral interval among investigated and non-investigated patients are small they are

positive for all cancers except for pancreatic (i.e., referral intervals are not shorter among investigated patients). Consequently, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated for all cancers except pancreatic cancer. Therefore, overall there is no evidence that longer primary-care intervals are offset by shorter referral intervals among patients who were investigated in primary care.